George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
The answer to your question is simple.
Insider trading.
With the knowledge they are sitting with, they are simply not allowed.
CEO, not VOE
I find Mr Sandler to have a high amount of integrity.
I am therefore baffled by people who calls for him to resign as CEO.
I cannot for the life of me see what a different CEO can bring to the table at this stage, other then an increased expense.
Mr. Sandler and team have acknowledged that the webpage is outdated, yet not done anything about.
There must be a reason for that.
Is it the expense? Is it their current workload? Do they prefer everything to be a bit cloak and dagger at the moment, or some totally different reason?
I don't know, I might newer find out, but I am sure there is a reason.
And that reason would still be in place with a different CEO, so there would not be a change in approach.
But the monthly expenditure for the payroll would have increased at a time where we have to work on a shoestring.
In my view that is not a smart move.
Mistakes have been made with financing, but we can all be doubed by others who have false intention.
And as Mr Sandler said afterwards he was glad for the money that they got and for that reason he did not regret it.
For me, that is integrity.
And I prefer that any day over a CEO spouting hot air to justify their pay.
We got all the info in official RNS's and we even occasionally get a tweet that shows something is happening.
And in my view, we are lucky that we have been able to hoover up shares at this level for as long as we have.
I am sure we are many who will have a lot to be thankful to Mr Sandler for in the years to come.
The science seems to be solid, based on the RNS's, there is no hot air statement, all is awesome in my view.
Will we need a new CEO, with more experience in running a business at some point in the future.
Yes, without a doubt.
But for now, at this stage, I commend Mr Sandler for being both the driving engine and VOE that he is.
It is a lot that is on his plate at the moment.
I was thrilled when I saw there was an RNS out, and I could not wait to read it.
Needless to say it did not contain the message that I was so hoping for. ( that HEMO is now clinical, or something down that line)
But, I assume that this is a housekeeping excersize before the big news starts rolling in next month.
Which coincidentally starts tomorrow.
Here's to hoping.
It's about a month ago we were told about Prevail Partners investing in Hemogenyx.
In the past we have been told that Mr Sandler would not reveal the partner that was lined up clinical trials before IND was sorted.
IND, has not Officially been sorted yet, but I believe that since the partner has been revealed it is as good as certain that it will be sorted successfully in the near future.
And I believe there is a good chance that it can happen this week as it is almost a month since we heard about Prevail.
And since then we have had fantastic news regarding CBR, well news can be discussed, but Mr Sandler has teasingly shown a device on social media that will be essential in the production of CBR.
And it is basically said an overgrown printer:-) and that is wonderful, because it makes it easy to scale up.
And Mr. Sandler and team have already had that planned for a while, just look at the following quote:
From RNS 13-7-2022
"Dr Vladislav Sandler, Co-Founder and CEO of Hemogenyx Pharmaceuticals said:
"I am thrilled to have moved into our customised and innovative lab space. The choice for our lab's continued growth was clear. With several current and future vivarium options, and the opportunity to collaborate with nearby world-class educational institutions including Columbia University and City College, the Mink Building offered an unmatched combination of advantages to operate and grow. Additionally, Janus was able to provide us with the future flexibility that is critical for us to continue to grow further."
I'll just repeat that again:
"Additionally, Janus was able to provide us with the future flexibility that is critical for us to continue to grow further."
As and if and when CBR has been proven, then Hemogenyx are ready to move and my understanding is that they will be able to move fast as there is no restriction from JANUS tying them in.
Quite the opposite, JANUS seems fully intent on helping the company grow.
The future is bright.
And I hope there will be a flash bang soon.
@Charles175
That is some impressive detective work you have done here, finding out which machine it was.
Very well done.
I am glad that you are a contributor on this board.
Showing if this piece of kit, was a wonderful little teaser from Mr Sandler in my view.
As investors, we now know that we do not need a huge factory hall with miles of pipes to manufacture CBR.
That is quite reassuring from a capital outlay point of view, although I am sure these machines does not come cheap either.
"A CBR mini-factory in action"
I like a message like that.
It looks like about 12 and 12 minutes left of the run when Mr. Sandler starts recording.
And more importantly, the run finishes at 2:10 AM.
That's in the middle of the night.
I call that commitment, as I assume that someone will have to be there and move it from the mini factory into a fridge or start testing it straight away.
In addition to potential news on the CBR front, I think the next couple of days are going to be interesting as we were informed on the 14-9-2023 that FDA had accepted the Clinical Hold Lift plan.
30 days are closing in (I hope)
As far as I am aware, the first day Hemogenyx was traded on the London Stock Exchange was on Monday the 9th of October 2017.
Wouldn't it be a poetic beauty if 6 years later, the company makes a seismic announcement in regard to any of our candidates.
The day is still young, so here is to hoping.
@HedgeHogarth
With every risk of sounding like a broken record;-)
I hope that it will merely be a break that you take, to take care of yourself.
Your contributions are much appreciated, not just by me, but by many I suspect.
Take a well-deserved break, I am looking forward to further good posts from you at some point in the future.
Stay awesome
@MrIndia
I disagree that the statements I have cut and pasted are vague.
I think they are very clear.
And that they tell us what news to expect to come.
“Attract high-level interest”
CBR is progressing and further resources will be allocated to this subject when time and money allow.
As today’s RNS was a half-year report, I expect it to be limited to what revolutionary news can be announced.
They are to follow in separate RNS’.
But hopefully these RNS’ will first come next month when I have a new allowance to invest and after the share price has dipped below 2 pence, so I can top up at a good price. (but hey, that is just me being selfish:-)
Do not forget, Mr Sandler can not control the share price, that is up to us investors and the Market Makers.
And today there was more selling than buying or the MM saw an opportunity to lower the price for one reason or another.
It does not matter to me one iota as I expect to be hugely rewarded for my patience.
And if I am lucky, that will be before the end of the year.
And if I am really lucky it will be within the next fortnight.
(But knowing my luck, I am not going to be that lucky)
If the following quote is Mr Sandler in his usual underplaying and overdelivering tone then this is ABSOLUTELY astonishing news, slash information that should comfort every investor.
“Meanwhile, the prospects for our other cutting-edge assets continue to be positive, and CBR in particular is beginning to attract real attention."
Further highlights in regard to CBR from the CBR section:
“Meanwhile, we have continued to work on our other major product candidates, in particular our Chimeric Bait Receptor”
“We have designed a set of novel CBR constructs to programme the immune cells that are responsible for innate immunity to eliminate viral infections.”
“Additionally, we have designed and currently test bait-macrophage engagers” (my emphasis is on the word TEST)
“The project has begun to attract high-level interest from authorities.”
“This interest is gratifying and, given our limited resources and the need to focus on our lead product HEMO-CAR-T, we have made considerable progress and plan to devote further internal resources to this project as soon as HEMO-CAR-T enters clinical trials.”
With HEMO-CAR-T planned to go into clinical trial later this year and the expected uplift in share price when that happens, I think the future is looking bright.
Unless there is a bad omen attached to HEMOGENYX we should be able to obtain funds for the further development of our products at a much higher share price than we got today.
Still down at this moment.
Hear hear for the latter option.
Hope to wake up to a brave new world tomorrow, and if that does not happen then a brand new updated website would be a nice consolation price:-)
@Cyrox
"Still peddling the idea that there was not a large premium paid by prevail for the privilege of running the trials. That is plain BS."
I would argue that Prevail haven't paid a dime.
In my view, they get to move money from one of their companies through HEMO and over in another of their companies.
In return they get just below 1percent if the shares in HEMO.
And they are likely to have forged a commercial bond that will last year's out in the future.
So they will essential Cary out the initial research for free, but in the long term, they are gaining big time.
But HEMO also gains from this deal.
Higher valuation and no or little upfront cost at this stage.
@JustHereForHemo
"if people on here or twitter dont agree? fair enough go buy something else, but dont pretend your smarter than a company whos very business model is investing in early clinical pharma and running trials"
This gotta be the qoute of the year.
Please keep them coming.
I assume that Mr. Sandler got to introduce CBR to a group of investors yesterday.
That was after establishing, through a partnership with Prevail, that a fair valuation point should be 6 pence and not sub 2 pence region.
So it is my hope that any potential professional investors accept to invest at 6 pence.
If we are unlucky, a discount is given from the 6 pence region, but at least that is better than the 2 pence region that it would have been by the end of last week.
And there is a good reason for professional investors to pay a premium if they see the potential game changers that Hemogenyx and CBR are.
It is better to give funds directly to the company, so it can work on its products than to buy the shares of me and any other John Doe.
Yes, currently they can buy the shares cheaper on the open market, but it would leave Hemogenyx with no additional funds to progress the development of their products.
And funds will be needed in the future.
Dengue is slowly getting a foothold in Europe, see the following link:
https://www.msn.com/en-gb/health/medical/deadly-virus-spreading-closer-to-uk-the-nine-symptoms-you-need-to-know/ar-AA1gT8Tp?ocid=msedgntp&cvid=28600c046abd42bcb46a8480f38a802c&ei=45
CBR is a potential candidate to solve that issue as it was RNS' on the 9th of January 2023 that CBR works against Dengue in the lab:
https://www.lse.co.uk/rns/HEMO/single-cbr-can-treat-multiple-viruses-btbliw44cz9mry8.html
But, Hemogenyx are not out of the lab yet.
And it will take funds to get it both to and through clinical trials.
These funds can be achieved either by investments (and thereby dilution) or by selling off HEMO CAR-T.
For now, I prefer further investment and dilution as long as it happens in the 6-pence region or above.
@dhub
Just to ensure we don't have a misunderstanding.
It's not about predicting in what order the news will arrive over the next couple of weeks/months.
It's about what would get people to buy more.
Especially new investors that have never heard about the company, but will as the news breaks.
One theory could be that it does not matter at all, as 5 pieces of good news is 5 pieces of good news.
Unfortunately, I do not believe it is as simple as that.
I think that the human psyche prefers a certain hierarchy, but I have no clue which one is the most predominant one.
Personally, I would like to see the clinical hold on Car-T lifted first, to make a name for ourselves.
Then I would like good news on CBR that reached the everyday man and woman in the world, followed by patent news, so no one is in doubt what Hemogenyx got.
And to just throw in Hulver's 6th element, I would like it to be followed up with 1 or more partnership agreements or a statement about the intention of making several partnership agreements.
Then news on a partnership in regard to CDX.
And finally, news that we still got money in the bank (Half year report)
The the half year statement
Today’s share price is just fantastic.
What a time to buy at this level.
Would I wish I first heard about Hemogenyx today, what their product line consists of and the potential news ahead?
You bet I would.
I would love to have the money that I have spent on shares in Hemogenyx over the last couple of years available and make my first buy now at this entry point.
But alas that is not the situation.
But some people out there have the chance of just being plain lucky if they buy in at this level for the first time.
Because if the science goes well….
Well, the world is our oyster.
If the science does not pan out as we hope, with all the candidates, well then, I think it is fair to say that all is lost.
So here is the thing, if you do not believe or hope (depending on your knowledge on the subject of Hemo’s product candidates) then you should not invest in the company today.
If you have already invested in the company but do not have any hope or belief in the chance of a positive outcome before we run out of funds, then it would be wise to sell your shares immediately and accept the loss.
Because of the simple reason, that some money in your pocket is better than none.
I belong to the group that hopes and believes that something good will come.
Eventually.
And I would like to hear from other like-minded LTH’s what domino effect of news they see as most likely to increase the share price.
What order of events would make you buy again and again if you first heard about Hemo today and had them on your radar, but would not fully commit a big sum straight away?
Simply because that is the sensible thing to do when it comes to biotech.
What is the best order of the following events?
1. Half year report
2. Clinical Hold lifted on Car-T
3. CBR patent going public for everyone to see
4. Positive news on CBR
5. Positive news on CDX
I hope the UK will work with Hemogenyx on Disease X
Hemogenyx has already been working on this stuff for a couple of years and hopefully have a good contender in CBR.
These guys are also using AI, a thing we know that Mr Sandler and the team are glad to use as well. And have used successfully.
https://www.msn.com/en-gb/health/medical/what-is-disease-x-uk-scientists-begin-work-on-vaccine-for-new-pandemic/ar-AA1eTIw5?ocid=msedgntp&cvid=f7ed2343168740b49b89da3626f0507e&ei=21
Wouldn't it be nice if they gave Hemogenyx a call when the worldwide patent for CBR is announced/revealed, sometime in the not-too-distant future?
If they can come up with something that works where CBR does not, then that would be awesome, as I do not expect CBR to be a catch-all phenomenon.
Nature, in my view, is simply too varied for that to be possible.
So for the sake of mankind, the more products out there, the better.
But boy, am I glad for the head start that Hemogenyx in my humble opinion has in this field.
@ Charles175
My understanding is that in vivo studies are taking place as we speak, in a government owned lab and that the research there, is out of Hemogenyx's control.
So I expect we will be told within days after Hemogenyx has been informed of the outcome.
And I for one, pray that we are not getting news while so many people are on holiday.
No let's wait until people are back and keen to invest and make a profit.
In the middle of the summer holiday, the responce is likely to be subdued.
@Steve196
Can you please explain in more detail what you mean by rocket on Google?
Hemogenyx has always come out as number one when you search on that name.
Has something happened when you Google CAR-T or CBR or anything else Hemo related?